At www.ValuEngine.com we show that the Medical sector 12.1% overvalued with the Medical Biomed / Genetics 13.7% overvalued. All 17 stocks in today’s table have complete ValuEngine data and have enough price data to have most value levels, risky levels and pivots.
Medgenics, Inc. (MDGN) – has been below $10 since the week of December 15, 2012.
MiMedx Group, Inc. (MDXG) – has been below $6.30 for at least five years.
MannKind Corp. (MNKD) – has been below $10 since the week of January 29, 2011.
Oncolytics Biotech Inc. (ONCY) – has been below $7 for at least five years.
Orexigen Therapeutics, Inc. (OREX) – has been below $10 since the week of February 12, 2011.
Osiris Therapeutics, Inc. (OSIR) – has been below $10 since the week of December 29, 2012.
Progenics Pharmaceuticals, Inc. (PGNX) – has been below $10 since the week of August 4, 2012.
Sunesis Pharmaceuticals, Inc. (SNSS) – has been below $10 since the week of December 29, 2009.
Synta Pharmaceuticals Corp. (SNTA) – has only been below $10 since February 15, 2013.
Sequenom Inc. (SQNM) – has been below $10 since the week of May 9, 2009.
Threshold Pharmaceuticals Inc. (THLD) – has been below $10 since the week of May 19, 2007.
Targacept, Inc. (TRGT) – has been below $10 since the week of November 19, 2011.
TrovaGene, Inc. (TROV) – has been below $9 for at least five years.
Vical, Inc. (VICL) – has been below $7 for at least five years.
Vanda Pharmaceuticals, Inc. (VNDA) – has been below $10 since the week of January 15, 2011.
Xenoport, Inc. (XNPT) – has been below $10 since the week of November 3, 2012.
XOMA Corp. (XOMA) – has been below $10 since the week of May 15, 2010.
Reading the Table
OV / UN Valued – The stocks with a red number are undervalued by this percentage. Those with a black number are overvalued by that percentage according to ValuEngine. The most undervalued stock is XOMA by 73.5%. The most overvalued stock is THLD by 65.2%.
VE Rating – A “1-Engine” rating is a Strong Sell, a “2-Engine” rating is a Sell, a “3-Engine” rating is a Hold, a “4-Engine” rating is a Buy and a “5-Engine” rating is a Strong Buy. All seventeen stocks are rated Hold.
Last 12-Month Return (%) – Stocks with a Red number declined by that percentage over the last twelve months. Stocks with a Black number increased by that percentage over the past twelve months! The biggest winner over the last twelve months is MDXG with a gain of 268.0%. The biggest loser was PGNX with a loss of 72.9%.
Forecast 1-Year Return – Stocks with a Red number are projected to decline by that percentage over the next twelve months. Stocks with a Black number in the Table are projected to move higher by that percentage over the next twelve months. These stocks are projected to trade between a decline of 4.8% and a gain of 3.9% over the next twelve months.
P/E Ratios – The twelve month trailing P/E ratios. None have P/E ratios.
Value Level: is the price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.
Pivot: A level between a value level and risky level that acts as a magnet during the time frame noted.
Risky Level: is the price at which to enter a GTC Limit Order to sell on strength.
Where to Buy and Where to Sell
A “Value Level” is a price at which buyers should add to positions on market price weakness. A “Risky Level” is a price at which sellers should reduce holdings on market price gains. A "Pivot" is a support or resistance (Value Level or Risky Level) that was violated in its time horizon, acting as a magnet during the remainder of that time horizon. These levels are calculated in weekly (W), monthly (M), quarterly (Q), semiannual (S) and annual (A) time horizons, based on the past nine closes in each time horizon. My theory is that the closes over a nine-year period are the summation of all bullish and bearish events for that market or specific stock. These levels are the most important element of my Buy and Trade Strategy.
Buy and Trade Guidelines
Investors should consider entering good until cancelled (GTC) orders to buy weakness to a value level, or to sell strength to a risky level.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer